Reasons why Boston is an ideal biotech hub for forging alliances

June 25, 2015 Erin Righetti

BostonBioPharm America™ 2015 plays an essential role in forging vital partnerships across the life science ecosystem for the benefit of each player, and the industry at large. The strength of a cluster can leverage the expertise of industry leaders with a critical mass of knowledge and innovation available in a concentrated hub like Boston.

Boston is an ideal biotech hub for forging alliances among the ecosystem for many reasons, including:

  • The life sciences corridor in Massachusetts combines the cities of Somerville, Cambridge, Boston, Quincy and Braintree, and is home to over 450 companies within the life science industry cluster.
  • There were USD 1,802 billion of venture investments in Massachusetts biotechs in 2014.
  • Massachusetts has seen 30 companies go public in the last two years.
  • Some of the largest biopharmaceutical companies in the world have a presence in the life sciences corridor, including Biogen, Boston Scientific, GlaxoSmithKline, Johnson & Johnson Innovation Center, Merck & Co., Novartis, Pfizer, Sanofi, Vertex Pharmaceuticals, and more.

Find more reasons in Spotlight on Boston. There won’t be a better time this year to engage with the rich life science ecosystem than this September 15–17. Register now to plan your Boston week at BioPharm America.


Erin Righetti is Editor of partnering360® Blog. Any views expressed are hers and not those of Informa.


Previous Article
Chile, a natural lab
Chile, a natural lab

Guest post by Arturo Covarrubias, President of Asembio A. G. and Lawyer and Managing Partner, Covarrubias &...

Next Article
CNS research sees some breakthroughs
CNS research sees some breakthroughs

Guest post by Hamish McDougall, Reporter at BioPharm Insight BioPharm Insight’s (BPI) editorial neurology r...